OZEMPIC 1.34 MG — DIN 02471469
SEMAGLUTIDE 1.34 MG · NOVO NORDISK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OZEMPIC?
OZEMPIC 1.34 MG contains SEMAGLUTIDE 1.34 MG. It is listed in the Health Canada Drug Product Database under DIN 02471469, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 22-Feb-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OZEMPIC used for?
OZEMPIC® is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control, in combination with: • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance. • metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control. • metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control. • metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i), when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do not achieve adequate glycemic control. • basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control (see 14 Clinical Trials). OZEMPIC® is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Semaglutide cost around the world?
Semaglutide is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 6 | 22 | SAR███.██ |
| Hungary | producer price (ex-factory) | 14 | 16 | HUF███.██ |
| Iceland | max wholesale | 5 | 16 | ISK███.██ |
| Luxembourg | reimbursement | 15 | 15 | EUR███.██ |
| United Arab Emirates | public | 12 | 14 | AED███.██ |
| Bahrain | retail (max) | 7 | 14 | BHD███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 2 | 11 | CZK███.██ |
| South Africa | single exit price | 8 | 11 | ZAR███.██ |
| Italy | prezzo al pubblico (classe A) | 9 | 10 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 6 | AUD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
151 pack listings across 95 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Semaglutide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Semaglutide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Semaglutide — 17 DINs, of which 9 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVO NORDISK CANADA INC | 17 | 9 | OZEMPIC, RYBELSUS, WEGOVY | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.34 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | OZEMPIC® is provided in a pre-filled, multi-dose, disposable pen, which contains the drug solution, semaglutide in a 1.5 mL or 3 mL cartridge. There are six variants of the pre-filled multi-dose pen for OZEMPIC®: - OZEMPIC® 0.25 mg, 0.5 mg/dose contains 1.5 mL solution, equivalent to 2 mg semaglutide (4 or 6 doses). - OZEMPIC® 0.25 mg, 0.5mg/dose contains 3 mL solution, equivalent to 2 mg semaglutide (4 or 6 doses). - OZEMPIC® 0.25 mg, 0.5mg/dose contains 3 mL, equivalent to 4 mg semaglutide (8 doses). - OZEMPIC® 1 mg/dose, contains 3 mL solution, equivalent to 4 mg semaglutide (4 doses). - OZEMPIC® 1 mg/dose contains 3 mL, equivalent to 8 mg semaglutide (8 doses). - OZEMPIC® 2 mg/dose, contains 3 mL solution, equivalent to 8 mg semaglutide (4 doses). Disposable needles are included in the OZEMPIC® package. Pack sizes of: Carton of 1 Pen • Pen delivers doses of 0.25 mg or 0.5 mg • 6 or 8 disposable needles • Intended to be used for dose escalation and maintenance treatment at the 0.5 mg dose Carton of 1 Pen • Pen delivers 1 mg doses • 4 or 8 disposable needles • Intended to be used for maintenance treatment at the 1 mg dose only Carton of 1 Pen • Pen delivers 2 mg doses • 4 disposable needles • Intended to be used for the maintenance treatment at the 2 mg dose only. |
| Storage | Before opening: Store in a refrigerator (2°C – 8°C). Do not freeze. Keep away from the cooling element. During use: You can keep the pen for 8 weeks when stored at a temperature below 30°C or in a refrigerator (2°C – 8°C). Do not freeze. When you are not using the pen, keep the pen cap on in order to protect it from light. Do not use this medicine if the solution is not clear and colourless. Do not leave the pen in a car or another place where it can get too hot or too cold. Do not inject OZEMPIC® which has been frozen. Do not inject OZEMPIC® which has been exposed to direct sunlight. Do not expose your pen to dust, dirt or liquid. Do not wash, soak or lubricate your pen. Do not drop your pen or knock it against hard surfaces. If you drop it or suspect a problem, attach a new needle and check the flow before you inject. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Semaglutide |
|---|---|
| ATC code | A10BJ06 |
| AHFS class | 68:20.06 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02471469 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2471469 |
| Brand name | OZEMPIC |
| Generic / active ingredient | SEMAGLUTIDE 1.34 MG |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10BJ06 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BJ |
| Current status | MARKETED |
| Status date | 22-Feb-2018 |
| Original market date | 2018-02-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
OZEMPIC® is to be administered once weekly, at any time of the day, with or without meals. OZEMPIC® should not be administered daily. The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours). OZEMPIC® can be used as monotherapy when metformin is not tolerated or is contraindicated, or as combination therapy with one or more antidiabetic drugs (metformin, sulfonylurea [SU], basal insulin, SGLT2i). OZEMPIC® should not be given in combination with other GLP-1 analogs. Combination with DPP-4 inhibitors has not been studied. When OZEMPIC® is added to existing metformin therapy, the current dose of metformin can be continued unchanged. An increased risk of hypoglycemia was seen with concomitant use of SU or basal insulin with OZEMPIC®. When OZEMPIC® is added to existing therapy of a sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycemia. In clinical trials, insulin dose was decreased by 20% at onset of OZEMPIC® treatment. See 7 Warnings and Precautions. Recommended Dose and Dosage Adjustment The recommended starting dose of OZEMPIC® is 0.25 mg once weekly. OZEMPIC® 0.25 mg is not a therapeutic dose. After 4 weeks, the dose should be increased to 0.5 mg once weekly. If additional glycemic control is needed after 4 weeks, the dose may be increased to 1 mg once weekly to further improve glycemic control. If additional glycemic control is needed after 4 weeks, the dose may be increased to 2 mg once weekly. The maximum recommended dose is 2 mg once weekly. OZEMPIC® is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site can be changed without dose adjustment. Inspect OZEMPIC® visually before use. It should appear clear and colourless. Do not use OZEMPIC® if particulate matter and colouration is seen. When using OZEMPIC® with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC® and insulin in the same body region but the injections should not be adjacent to each other. Rotate injection sites with each dose. Do not use the same site for each injection. OZEMPIC® should not be administered intravenously or intramuscularly. Missed Dose If a dose is missed, it should be administered as soon as possible within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
OZEMPIC® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). OZEMPIC® is contraindicated in patients with hypersensitivity to OZEMPIC® or to any of the product components. OZEMPIC® should not be used during pregnancy or breastfeeding. OZEMPIC® should not be used in patients with type 1 diabetes mellitus (formerly known as insulin-dependent diabetes mellitus or IDDM) or for the treatment of diabetic ketoacidosis.
Warnings and precautions
Risk of Thyroid C-cell Tumours: Semaglutide causes treatment-dependent thyroid C-cell tumours at clinically relevant exposures in both sexes of rats and mice. It is unknown whether semaglutide causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans, as human relevance could not be ruled out by clinical or nonclinical studies. OZEMPIC® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is unknown whether monitoring with serum calcitonin or thyroid ultrasound will mitigate human risk of thyroid C-cell tumours. Patients should be counseled regarding the risk and symptoms of thyroid tumours (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Cardiovascular: OZEMPIC® causes an increase in heart rate and a prolongation of the PR interval of the electrocardiogram. Caution should be observed in patients who have cardiac conditions that might be worsened by an increase in heart rate, such as tachyarrhythmias, or with pre-existing conduction system abnormalities. Hypoglycemia: Increased risk of hypoglycemia with concomitant use of sulfonylurea or basal insulin. Dose reduction of sulfonylurea or insulin should be considered. Gastrointestinal: Use of GLP-1 receptor agonists may be associated with severe gastrointestinal disease (ileus). Events of delayed gastric emptying, dysgeusia, intestinal obstruction, and ileus have been reported. Pancreatitis: Acute pancreatitis has been observed with the use of GLP-1 receptor agonists. If pancreatitis is suspected, OZEMPIC® should be discontinued. Acute Gall Bladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported. If suspected, gallbladder studies and appropriate clinical follow-up are indicated. Hypersensitivity: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur. If a hypersensitivity reaction occurs, discontinue OZEMPIC® and promptly seek medical advice. Diabetic Retinopathy Complications: More events of diabetic retinopathy complications occurred in patients treated with OZEMPIC® in a 2-year trial. Rapid improvement in glucose control may lead to temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored. Renal Insufficiency: Use with caution in patients with impaired renal function as gastrointestinal adverse reactions may cause dehydration and deterioration of renal function. Monitor renal function.
Is Semaglutide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by DR REDDY'S LABORATORIES LTD (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 17 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OZEMPIC | 0.68 MG | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02540258 |
| RYBELSUS | 1.5 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02551012 |
| RYBELSUS | 4 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02551020 |
| RYBELSUS | 9 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02551039 |
| RYBELSUS | 3 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02497581 |
| RYBELSUS | 7 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02497603 |
| RYBELSUS | 14 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02497611 |
| WEGOVY | 4 MG / 3 ML | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02528525 |
| OZEMPIC | 2.68 MG | SOLUTION | NOVO NORDISK CANADA INC | APPROVED | 02523930 |
| OZEMPIC | 1.34 MG | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | 02471477 |
2 · Same class — other molecules in ATC A10BJ
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Semaglutide | OZEMPIC · RYBELSUS · WEGOVY | 17 | 9 | Yes |
| Dulaglutide | TRULICITY | 6 | 2 | Yes |
| Liraglutide | SAXENDA · VICTOZA | 2 | 2 | Yes |
| Exenatide | BYDUREON · BYDUREON BCISE · BYETTA | 4 | 0 | Not in Canada |
| Lixisenatide | ADLYXINE | 3 | 0 | Not in Canada |
| Albiglutide | EPERZAN | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BB | Acetohexamide · Chlorpropamide · Glibenclamide · Gliclazide · Glimepiride · +1 more | 112 | 23 |
| A10BG | Pioglitazone · Rosiglitazone | 98 | 15 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OZEMPIC called?
Also recorded in Canada as: 0.25 MG, 0.5 MG Dose 1.5 ML semaglutide 1.34 MG/ML Pen Injector [Ozempic] (US), semaglutide 14 MG Oral Tablet [Rybelsus] (US), semaglutide 3 MG Oral Tablet [Rybelsus] (US), semaglutide 7 MG Oral Tablet [Rybelsus] (US), 3 ML semaglutide 1.34 MG/ML Pen Injector [Ozempic] (US), 0.5 ML semaglutide 0.5 MG/ML Auto-Injector [Wegovy] (US), 0.5 ML semaglutide 1 MG/ML Auto-Injector [Wegovy] (US), 0.5 ML semaglutide 2 MG/ML Auto-Injector [Wegovy] (US), 0.75 ML semaglutide 2.27 MG/ML Auto-Injector [Wegovy] (US), 0.75 ML semaglutide 3.2 MG/ML Auto-Injector [Wegovy] (US), 3 ML semaglutide 2.68 MG/ML Pen Injector [Ozempic] (US), 0.25 MG, 0.5 MG Dose 3 ML semaglutide 0.68 MG/ML Pen Injector [Ozempic] (US), semaglutide 1.5 MG Oral Tablet [Rybelsus] (US), semaglutide 4 MG Oral Tablet [Rybelsus] (US), semaglutide 9 MG Oral Tablet [Rybelsus] (US).
The same molecule, Semaglutide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Rybelsus | Latin | Bahrain, Czechia, Iceland, Saudi Arabia |
| Wegovy | Latin | Iceland, Saudi Arabia |
| Tasylev | Latin | Saudi Arabia |
| Ozempic (Abacus Medicine) | Latin | Iceland |
| Extensior | Latin | South Africa |
| Glucentra | Latin | Saudi Arabia |
| Lugyda | Latin | Saudi Arabia |
| Semagard | Latin | South Africa |
| Ozempic (Lyfjaver) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.